Medical Mycology Journal
Online ISSN : 2186-165X
Print ISSN : 2185-6486
ISSN-L : 2185-6486
Diagnosis and Treatment of Mucormycosis in Patients with Hematological Malignancies
Yuki Asano-Mori
Author information

2016 Volume 57 Issue 4 Pages J155-J162


The risk of invasive fungal infections (IFIs) is extremely high in patients with hematological malignancies due to the prolonged and profound neutropenia and immunosuppression after chemotherapy and hematopoietic stem cell transplantation. There has been increasing interest in mucormycosis despite its relatively uncommon occurrence, because occasional breakthrough infections have been observed under anti-aspergillus prophylaxis. The aggressive nature of mucormycosis easily leads to high mortality because of delays in diagnosis and incorrect treatment decisions, which are due in part to lack of adjunctive diagnostic tools and having similar clinical and radiological features with aspergillosis. The only currently available antifungals against Mucorales in Japan are amphotericin B formulations. Thus, comprehensive therapeutic strategies, including surgery, should be considered in order to achieve a successful outcome.

Content from these authors
© 2016 The Japanese Society for Medical Mycology
Previous article Next article